EU/3/16/1644: Orphan designation for the prevention of cytomegalovirus disease



On 28 April 2016, orphan designation (EU/3/16/1644) was granted by the European Commission to Chimerix UK Ltd, United Kingdom, for brincidofovir for the prevention of cytomegalovirus disease.

The sponsorship was transferred to Chimerix IRL Limited, Ireland, in April 2019.

Key facts

Active substance
Intended use
Prevention of cytomegalovirus disease
Orphan designation status
EU designation number
Date of designation

Chimerix IRL Limited
10 Earlsfort Terrace
Dublin 2, Co. Dublin
Tel. +353 1920 1572

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating
1 rating